Alnylam Pharmaceuticals logo
|
|
Type
|
Public |
---|---|
Traded as | NASDAQ: ALNY |
Industry | Pharmaceutical |
Founded | 2002 |
Headquarters | Cambridge, MA, USA |
Key people
|
John Maraganore, (CEO) |
Number of employees
|
> 500 (2017) |
Website | Alnylam.com |
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
In 2002, Alnylam was founded by scientists Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, and Phillip Zamore, and by investors Christoph Westphal and John Kennedy Clarke; John Maraganore was the founding CEO. The company was named after Alnilam, a star in Orion’s belt. The spelling was modified to make it unique. In 2003, the firm merged with the German pharmaceutical company, Ribopharma AG. The newly formed company also received $24.6 million in funding from private-equity firms. On February 27, 2004, Alnylam Pharmaceuticals filed for an IPO. The company raised $26 million and began trading as ALNY on the Nasdaq stock exchange.
In 2005, the company partnered with Medtronic to develop drug-device combinations to treat neurodegenerative disorders; and in 2006 with Biogen Idec to develop treatments of progressive multifocal leukoencephalopathy; In 2007, it entered into a nonexclusive alliance with Hoffmann-La Roche, in which Alnylam received $331 million in exchange for access to its technology platform. an dalso partnered with Isis Pharmaceuticals to found the company Regulus Therapeutics, focused on microRNA therapeutics.
In 2009, the company formed alliances with Cubist Pharmaceuticals and Kyowa Hakko Kirin to market a drug targeted at respiratory syncytial virus. In 2010, it expanded its previous collaboration with Medtronic to include the CHDI Foundation in its Huntington's Disease focused research . In 2011, it partnered with GlaxoSmithKline to develop RNAi technology enhancing vaccine production. The company entered into a 10-year alliance with Monsanto in 2012, to develop biotech solutions for the farming industry by developing natural molecules for crop protection. In 2012, it formed a partnership with Sanofi Genzyme to develop a treatment for transthyretin-mediated amyloidosis, a hereditary disease in Asia. In February 2013, it formed a partnership with The Medicines Company to develop a drug to treat a genetic form of high cholesterol.
In July 2013, during a Phase I trial Alnylam demonstrated statistically significant reduction of a protein called transthyretin, or TTR and demonstrated human efficacy with intravenous and subcutaneous modes of administration. In 2014, Sanofi Genzyme acquired a 12 percent stake in Alnylam and increased its rights to several of the company's drugs for $700 million. In a separate transaction Alnylam announced that it had purchased Merck & Co.'s Sirna Therapeutics, for $25 million cash and $150 million in stock. In 2015, the company had $41 million in revenue and a market cap of $5.2 billion.
In 2016, the company purchased land in Norton, Massachusetts to build a manufacturing facility.
In October 2016 the Phase III clinical trial of the company's lead product, revusiran, was halted due to increased deaths in the drug arm of the trial, and the company said it was terminating development of the compound.
In 2016, Alnylam Pharmaceuticals had 18 potential treatments in various development stages in Genetic Medicine, Cardio-Metabolic Disease and Hepatic Infectious Disease. In late 2016, the company's lead candidate in phase III studies was patisiran, a treatment targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR), in patients with familial amyloidotic polyneuropathy (FAP).
Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q3 2022 | 2022-10-26 | Future report Set alerts | |
Q2 2022 | 2022-07-28 | -2.29 | -2.29 |
Q1 2022 | 2022-04-28 | -2.00 | -2.00 |
Q4 2021 | 2022-02-10 | -2.16 | -2.16 |
Q3 2021 | 2021-10-28 | -1.72 | -1.72 |
Q2 2021 | 2021-08-03 | -1.61 | -1.61 |
Q1 2021 | 2021-04-29 | -1.71 | -1.71 |
Q4 2020 | 2021-02-11 | -2.09 | -2.09 |
Q3 2020 | 2020-11-05 | -2.18 | -2.18 |
Q2 2020 | 2020-08-06 | -1.56 | -1.56 |
2016-07-11 | Reiterated Rating | Chardan Capital | Buy | |
2016-07-10 | Reiterated Rating | JMP Securities | Buy | |
2016-07-05 | Reiterated Rating | FBR & Co | Outperform | $180.00 |
2016-07-05 | Reiterated Rating | Cowen and Company | Buy | $150.00 |
2016-07-01 | Reiterated Rating | Needham & Company LLC | Buy | $152.00 |
2016-06-30 | Reiterated Rating | Jefferies Group | Buy | |
2016-06-23 | Reiterated Rating | JMP Securities | Buy | $127.00 |
2016-06-13 | Reiterated Rating | Needham & Company LLC | Buy | |
2016-06-12 | Reiterated Rating | Credit Suisse | Buy | |
2016-06-12 | Reiterated Rating | Leerink Swann | Buy | |
2016-06-12 | Reiterated Rating | Cowen and Company | Buy | |
2016-06-12 | Reiterated Rating | Credit Suisse Group AG | Buy | |
2016-06-10 | Reiterated Rating | FBR & Co. | Buy | |
2016-06-10 | Reiterated Rating | FBR & Co | Buy | |
2016-06-08 | Reiterated Rating | Jefferies Group | Buy | $119.00 to $80.00 |
2016-05-26 | Lower Price Target | Chardan Capital | Buy | $115.00 to $93.00 |
2016-05-26 | Reiterated Rating | Piper Jaffray | Buy | |
2016-05-26 | Reiterated Rating | Piper Jaffray Cos. | Buy | |
2016-05-22 | Reiterated Rating | Cowen and Company | Buy | |
2016-05-04 | Reiterated Rating | Jefferies Group | Buy | $122.00 to $119.00 |
2016-05-04 | Reiterated Rating | Needham & Company LLC | Buy | |
2016-05-03 | Reiterated Rating | Cowen and Company | Buy | |
2016-05-03 | Lower Price Target | Leerink Swann | Outperform | $120.00 to $107.00 |
2016-04-29 | Reiterated Rating | FBR & Co. | Buy | |
2016-04-19 | Reiterated Rating | Jefferies Group | Buy | $122.00 |
2016-04-17 | Reiterated Rating | Cowen and Company | Buy | |
2016-04-14 | Reiterated Rating | Chardan Capital | Buy | |
2016-04-04 | Initiated Coverage | Chardan Capital | Buy | $93.00 |
2016-03-11 | Upgrade | JPMorgan Chase & Co. | Neutral to Overweight | $111.00 to $81.00 |
2016-03-10 | Reiterated Rating | Cowen and Company | Buy | |
2016-03-09 | Lower Price Target | JMP Securities | Market Outperform | $144.00 to $135.00 |
2016-03-09 | Lower Price Target | JPMorgan Chase & Co. | Market Outperform | $144.00 to $135.00 |
2016-02-22 | Lower Price Target | Goldman Sachs | $107.00 to $70.00 | |
2016-02-22 | Lower Price Target | Goldman Sachs Group Inc. | $107.00 to $70.00 | |
2016-02-16 | Lower Price Target | Leerink Swann | Outperform | $152.00 to $120.00 |
2016-02-16 | Reiterated Rating | FBR & Co. | Outperform | $180.00 |
2016-02-14 | Reiterated Rating | Piper Jaffray | Overweight | $184.00 to $102.00 |
2016-02-12 | Reiterated Rating | Cowen and Company | Buy | $150.00 |
2016-01-29 | Reiterated Rating | FBR & Co. | Outperform | $180.00 |
2016-01-28 | Initiated Coverage | FBR & Co. | Buy | |
2016-01-19 | Initiated Coverage | Credit Suisse | Outperform | $154.00 |
2016-01-12 | Reiterated Rating | Cowen and Company | Outperform | $150.00 |
2016-01-05 | Reiterated Rating | Piper Jaffray | Overweight | $184.00 |
2015-12-13 | Reiterated Rating | Needham & Company LLC | Buy | |
2015-12-07 | Reiterated Rating | Cowen and Company | Buy | $150.00 |
2015-12-07 | Initiated Coverage | Needham & Company LLC | Buy | |
2015-11-30 | Reiterated Rating | Leerink Swann | Outperform | |
2015-11-26 | Downgrade | S&P Equity Research | Buy to Hold | |
2015-11-10 | Boost Price Target | Leerink Swann | Outperform | $151.00 to $152.00 |
2015-11-10 | Boost Price Target | Jefferies Group | Buy | $107.00 to $126.00 |
2015-11-08 | Reiterated Rating | FBR & Co. | Buy | $180.00 |
2015-11-04 | Reiterated Rating | Needham & Company LLC | Buy | $152.00 |
2015-10-22 | Initiated Coverage | Jefferies Group | Buy | $107.00 |
2015-10-13 | Reiterated Rating | FBR & Co. | Buy | $180.00 |
2015-09-29 | Reiterated Rating | Piper Jaffray | Buy | |
2015-09-22 | Reiterated Rating | Piper Jaffray | Buy | |
2015-09-15 | Reiterated Rating | Needham & Company LLC | Buy | $152.00 |
2015-08-31 | Boost Price Target | Leerink Swann | Outperform | $145.00 to $151.00 |
2015-08-31 | Reiterated Rating | Needham & Company LLC | Buy to Buy | $152.00 |
2015-08-31 | Boost Price Target | Piper Jaffray | Overweight | $180.00 to $184.00 |
2015-08-28 | Reiterated Rating | JMP Securities | Outperform | $144.00 |
2015-08-17 | Reiterated Rating | Leerink Swann | Outperform | $145.00 |
2015-08-11 | Initiated Coverage | FBR & Co. | Outperform | $180.00 |
2015-08-07 | Reiterated Rating | Needham & Company LLC | Buy | $152.00 |
2015-08-07 | Downgrade | JPMorgan Chase & Co. | Overweight to Neutral | $125.00 to $115.00 |
2015-07-02 | Reiterated Rating | Piper Jaffray | Outperform | $150.00 to $180.00 |
2015-06-24 | Set Price Target | Deutsche Bank | Buy | $155.00 |
2015-06-24 | Set Price Target | Cowen and Company | Buy | $150.00 |
2015-06-24 | Reiterated Rating | Canaccord Genuity | Buy | $160.00 |
2015-06-24 | Reiterated Rating | Needham & Company LLC | Buy | $152.00 |
2015-06-24 | Set Price Target | Deutsche Bank AG | Buy | $155.00 |
2015-06-15 | Reiterated Rating | Deutsche Bank | Positive | |
2015-06-15 | Boost Price Target | Piper Jaffray | Overweight | $155.00 to $180.00 |
2015-06-14 | Reiterated Rating | Needham & Company LLC | Buy | $152.00 |
2015-06-12 | Set Price Target | Deutsche Bank | Buy | $155.00 |
2015-06-05 | Reiterated Rating | Canaccord Genuity | Buy | $160.00 |
2015-05-26 | Reiterated Rating | Canaccord Genuity | Buy | $160.00 |
2015-05-18 | Set Price Target | Canaccord Genuity | Buy | $160.00 |
2015-05-08 | Set Price Target | Needham & Company LLC | Buy | $152.00 |
2015-05-08 | Set Price Target | Canaccord Genuity | Buy | $160.00 |
2015-04-21 | Boost Price Target | Leerink Swann | $145.00 | |
2015-04-21 | Boost Price Target | Needham & Company LLC | Buy | $120.00 to $152.00 |
2015-04-16 | Reiterated Rating | Canaccord Genuity | Buy | $160.00 |
2015-03-17 | Initiated Coverage | Janney Montgomery Scott | Buy | $139.00 |
2015-03-03 | Initiated Coverage | Barclays | Overweight | $125.00 |
2015-03-03 | Initiated Coverage | Barclays PLC | Overweight | $125.00 |
2015-02-27 | Initiated Coverage | Cowen and Company | Outperform | $150.00 |
2015-02-25 | Reiterated Rating | Canaccord Genuity | Buy | $160.00 |
2015-02-13 | Set Price Target | Needham & Company LLC | Buy | $120.00 |
2015-02-08 | Set Price Target | Canaccord Genuity | Buy | $160.00 |
2015-01-08 | Boost Price Target | Deutsche Bank | $155.00 | |
2015-01-07 | Initiated Coverage | Canaccord Genuity | Buy | |
2014-12-30 | Initiated Coverage | Goldman Sachs | Neutral | |
2014-12-24 | Boost Price Target | JPMorgan Chase & Co. | Overweight | $90.00 to $106.00 |
2014-12-15 | Boost Price Target | Piper Jaffray | Overweight | $134.00 to $158.00 |
2014-12-12 | Initiated Coverage | Goldman Sachs | Neutral | $113.00 |
2014-11-17 | Reiterated | Needham | Buy | $94 to $120 |
2014-11-17 | Boost Price Target | Needham & Company LLC | Buy | $94.00 to $120.00 |
2014-09-18 | Initiated Coverage | Leerink Swann | Outperform | $103.00 |
2014-02-14 | Reiterated | Needham | Buy | $65 to $84 |
2014-02-14 | Boost Price Target | Needham & Company LLC | Buy | $65.00 to $84.00 |
2014-01-31 | Boost Price Target | JMP Securities | $68.00 to $110.00 | |
2014-01-17 | Boost Price Target | Deutsche Bank | Buy | $80.00 to $108.00 |
2014-01-14 | Downgrade | Morgan Stanley | Overweight to Equal Weight | $72.00 to $54.00 |
2014-01-13 | Downgrade | S&P Equity Research | Neutral | |
2014-01-13 | Reiterated Rating | JMP Securities | Market Perform | |
2013-11-11 | Boost Price Target | Leerink Swann | Outperform | $80.00 to $82.00 |
2013-09-24 | Boost Price Target | Deutsche Bank | Buy | $60.00 to $80.00 |
2013-09-24 | Reiterated | |||
2013-09-23 | Upgrade | Needham & Company LLC | Positive | $55.00 to $65.00 |
2013-09-23 | Boost Price Target | Leerink Swann | Outperform | $57.00 to $80.00 |
2013-08-09 | Reiterated | Needham | Buy | $40 to $55 |
2013-07-01 | Reiterated | Needham | Buy | $28 to $40 |
2013-02-11 | Downgrade | MLV & Co | Buy to Hold | $20 to $27.50 |
2012-07-16 | Reiterated | Needham | Buy | $16 to $20 |
2012-02-10 | Reiterated | JMP Securities | Mkt Outperform | $12 to $17 |
2011-12-15 | Initiated | JMP Securities | Mkt Outperform | $12 |
2011-10-14 | Initiated | Rodman & Renshaw | Mkt Outperform | $12 |
2011-05-06 | Initiated | MLV Capital | Buy | $15 |
2010-09-24 | Reiterated | Rodman & Renshaw | Mkt Outperform | $37 to $24 |
2010-05-20 | Initiated | ThinkEquity | Buy | |
2009-11-24 | Downgrade | Roth Capital | Buy to Hold | $26 to $17 |
2009-06-10 | Initiated | Roth Capital | Buy | $26 |
2009-06-10 | Initiated | Jefferies & Co | Buy | $28 |
2009-02-25 | Upgrade | Needham | Underperform to Hold | |
2008-08-20 | Initiated | Leerink Swann | Underperform | $15 |
2008-03-03 | Downgrade | Needham & Co | Hold to Underperform |
2016-07-11 | Reiterated Rating | Chardan Capital | Buy | |
2016-07-10 | Reiterated Rating | JMP Securities | Buy | |
2016-07-05 | Reiterated Rating | FBR & Co | Outperform | $180.00 |
2016-07-05 | Reiterated Rating | Cowen and Company | Buy | $150.00 |
2016-07-01 | Reiterated Rating | Needham & Company LLC | Buy | $152.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In ALNY 329 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
Nuveen Asset Management, LLC | 16.59M |
Capital World Investors | 13.95M |
FMR LLC | 12.95M |
Vanguard Group, Inc | 11.05M |
BAILLIE GIFFORD & CO | 9.51M |
BlackRock Inc. | 7.67M |
WELLINGTON MANAGEMENT CO LLP | 5.95M |
DODGE & COX | 4.89M |
PRICE T ROWE ASSOCIATES INC /MD/ | 3.72M |
STATE STREET CORP | 2.80M |
JPMORGAN CHASE & CO | 2.55M |
BlackRock Fund Advisors | 2.10M |
BlackRock Institutional Trust Company, N.A. | 1.95M |
Capital International Investors | 1.95M |
RTW INVESTMENTS, LLC | 1.68M |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
SANOFI-AVENTIS | 13.82% (10554134) | ALNY / KBIO / REGN / RGLS / |
ALNYLAM PHARMACEUTICALS, INC. | 7.89% (6021900) | ALNY / RGLS / |
NOVARTIS AG | 5.31% (4051002) | ALNY / IDIX / |
MARAGANORE JOHN CEO | 0.20% (151297) | AGIO / ALNY / BLUE / RGLS / |
SHARP PHILIP A | 0.18% (140795) | ALNY / |
Greene Barry E President and COO | 0.08% (61968) | ACOR / ALNY / KPTI / RGLS / |
Reid Laurence SVP, Chief Business Officer | 0.02% (18103) | ALNY / |
KEATING LAURIE SVP, GC and Secretary | 0.02% (14500) | ALNY / |
Vaishnaw Akshay SVP, Chief Medical Officer | 0.01% (11215) | ALNY / |
Mason Michael VP, Finance and Treasurer | 0.01% (6352) | ALNY / |
BONNEY MICHAEL W | 0.01% (4000) | ALNY / CBST / CELG / HQH / HQL / NPSP / SRPT / |